Psoriatic arthritis (PsA), a chronic inflammatory condition characterized by dactylitis, enthesitis, peripheral arthritis, skin and nail psoriasis, and spondylitis, occurs in around 10%-30% of people ...

Psoriatic arthritis can progress over time, and bone issues such as osteoporosis can crop up with age. Try these tips to protect your bones and joints through the years.

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Anyone can develop psoriatic arthritis, but it’s most common in people who already have psoriasis, affecting about 30 percent of people with the skin condition. Whether you’re managing just psoriatic ...

UCB has announced positive topline results from its BE BOLD trial, the first head‑to‑head study in active psoriatic arthritis to demonstrate superiority of one licensed biologic therapy over an IL‑23 ...

Add Yahoo as a preferred source to see more of our stories on Google. Dealing with the itchy, scaly patches that come with psoriasis is difficult enough. But having psoriasis puts you at risk of ...

Note: The U.S. Food and Drug Administration (FDA) does not approve supplements for safety or effectiveness. Talk to a healthcare professional about whether a supplement is the right fit for your ...

Psoriatic arthritis is a chronic inflammatory condition that can significantly impact the quality of life of those affected. Understanding where and how this disease manifests in the body can help in ...

Joni Kazantzis was diagnosed with psoriasis at 15 and received a psoriatic arthritis diagnosis during the pandemic. She created a blog and social platform to offer the guidance she once ...

There was a point a few years ago that Chef Michelle Bernstein thought her livelihood was finished. The James Beard Award-winning chef, who has appeared on cooking competitions like Top Chef and ...

At week 16, both trials showed a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response compared with placebo. Topline data were announced from two phase 3 trials ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...